StockData
UNITED THERAPEUTICS Corp logo

UNITED THERAPEUTICS Corp (UTHR) stock

UTHRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3022% above fair value
$584.10−3.78 (-0.64%)

Close on Nov 17, 2026Market cap $25.05BP/E 20.9Yield –

United Therapeutics cash

Cash and short-term investments held at the end of each period.

United Therapeutics's cash was $2.66B at Jun 30, 2026. For fiscal 2025 it was $2.92B, down 10.6% from the year before. Over ten years it grew 13.4% a year on average. The highest annual figure on record is $3.27B in fiscal 2024.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.92B-10.6%
FY2024Dec 31, 2024$3.27B+9.1%
FY2023Dec 31, 2023$2.99B+5.5%
FY2022Dec 31, 2022$2.84B+47.0%
FY2021Dec 31, 2021$1.93B+5.2%
FY2020Dec 31, 2020$1.84B+23.5%
FY2019Dec 31, 2019$1.49B+4.9%
FY2018Dec 31, 2018$1.42B+52.7%
FY2017Dec 31, 2017$927.40M-11.7%
FY2016Dec 31, 2016$1.05B+26.3%
FY2015Dec 31, 2015$831.80M+109.2%
FY2014Dec 31, 2014$397.70M+39.9%
FY2013Dec 31, 2013$284.30M+78.4%
FY2012Dec 31, 2012$159.40M-5.1%
FY2011Dec 31, 2011$168.05M-33.4%
FY2010Dec 31, 2010$252.16M+151.3%
FY2009Dec 31, 2009$100.35M-22.5%
FY2008Dec 31, 2008$129.45M-7.1%
FY2007Dec 31, 2007$139.32M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.66B-12.7%
Q1 FY2026Mar 31, 2026$2.15B-35.2%
Q4 FY2025Dec 31, 2025$2.92B-10.6%
Q3 FY2025Sep 30, 2025$2.77B-16.8%
Q2 FY2025Jun 30, 2025$3.05B+2.6%
Q1 FY2025Mar 31, 2025$3.32B+22.7%
Q4 FY2024Dec 31, 2024$3.27B+9.1%
Q3 FY2024Sep 30, 2024$3.33B+15.7%
Q2 FY2024Jun 30, 2024$2.97B+10.9%
Q1 FY2024Mar 31, 2024$2.71B-5.4%
Q4 FY2023Dec 31, 2023$2.99B+5.5%
Q3 FY2023Sep 30, 2023$2.88B+9.9%
Q2 FY2023Jun 30, 2023$2.68B+18.8%
Q1 FY2023Mar 31, 2023$2.86B+26.3%
Q4 FY2022Dec 31, 2022$2.84B+47.0%
Q3 FY2022Sep 30, 2022$2.62B+30.8%
Q2 FY2022Jun 30, 2022$2.26B+14.6%
Q1 FY2022Mar 31, 2022$2.27B+31.0%
Q4 FY2021Dec 31, 2021$1.93B+5.2%
Q3 FY2021Sep 30, 2021$2.00B+26.6%
Q2 FY2021Jun 30, 2021$1.97B+26.1%
Q1 FY2021Mar 31, 2021$1.73B+12.1%
Q4 FY2020Dec 31, 2020$1.84B+23.5%
Q3 FY2020Sep 30, 2020$1.58B+0.7%
Q2 FY2020Jun 30, 2020$1.56B-12.6%
Q1 FY2020Mar 31, 2020$1.54B-3.8%
Q4 FY2019Dec 31, 2019$1.49B+4.9%
Q3 FY2019Sep 30, 2019$1.57B+26.9%
Q2 FY2019Jun 30, 2019$1.79B+47.3%
Q1 FY2019Mar 31, 2019$1.61B+27.7%
Q4 FY2018Dec 31, 2018$1.42B+52.7%
Q3 FY2018Sep 30, 2018$1.24B+2.2%
Q2 FY2018Jun 30, 2018$1.21B+8.8%
Q1 FY2018Mar 31, 2018$1.26B+8.7%
Q4 FY2017Dec 31, 2017$927.40M-11.7%
Q3 FY2017Sep 30, 2017$1.21B+27.0%
Q2 FY2017Jun 30, 2017$1.12B–
Q1 FY2017Mar 31, 2017$1.16B–
Q4 FY2016Dec 31, 2016$1.05B–
Q3 FY2016Sep 30, 2016$953.00M–

More United Therapeutics figures

See a number that looks wrong?